Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Combining different anti-cancer immunotherapies is currently a major focus of clinical oncology studies, but while this can increase efficacy this benefit usually comes at a price of increased, dose limiting toxicity. Because these agents are dosed systemically, they frequently cause unwanted immune inflammation in a variety of organ systems as well as in the intended tumor lesions.
Tumor re-engineering aims to overcome these issues by enabling selective delivery to and/or production of the therapeutic agent or combinations in tumor tissues where they are needed while minimizing systemic exposure. We are developing a tumor-specific immune-gene (T-SIGn) vector approach that delivers biotherapeutic gene payloads for production by the tumor cells themselves. These aim to promote anti-tumor immunity from within the lesions by targeting elements of the tumor and local lymphoid microenvironments. This presentation will use data generated with different clinical and preclinical stage T-SIGn candidates to illustrate these concepts.
